LAG3 and diffuse large B-cell lymphoma: These findings emphasize the need to explore LAG‐3 expression and its interaction with other markers, such as C‐X‐C chemokine receptor type 5 (CXCR5), to better understand their prognostic significance and therapeutic potential in DLBCL.